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Summary
The transcriptional mechanisms underlying lineage
specification and differentiation of embryonic stem
(ES) cells remain elusive. Oct-3/4 (POU5f1) is one of
the earliest transcription factors expressed in the em-
bryo. Both the pluripotency and the fate of ES cells
depend upon a tight control of Oct-3/4 expression.
We report that transgene- or TGFb-induced increase
in Oct-3/4 mRNA and protein levels in undifferentiated
ES cells and at early stages of differentiation triggers
expression of mesodermal and cardiac specific genes
through Smad2/4. cDNA antisense- and siRNA-
mediated inhibition of upregulation of Oct-3/4 in ES
cells prevent their specification toward the mesoderm
and their differentiation into cardiomyocytes. Simi-
larly, Oct-3/4 siRNA injected in the inner cell mass of
blastocysts impairs cardiogenesis in early embryos.
Thus, quantitative Oct-3/4 expression is regulated by
a morphogen, pointing to a pivotal and physiological
function of the POU factor in mesodermal and cardiac
commitments of ES cells and of the epiblast.
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Pluripotent embryonic stem (ES) cells derived from the
inner cell mass (ICM) of the blastocyst are capable of
giving rise to different progeny representative of the
three embryonic layers, namely, the endoderm, meso-
derm, and ectoderm. ES cells have the capability to
self-renew and to differentiate. Cell commitment or
specification is a process by which an undifferentiated
cell enters a developmental pathway. Such a biological
event, which precedes differentiation per se, is revers-
ible, as opposed to cell determination, which defines
an irreversible differentiation state (Slack, 1991). Speci-
fication takes place following cell stimulation with
growth factors or morphogens (Wolpert, 1989). The
molecular mechanisms which involve tissue-specific
transcription factors and underlie this process are still
poorly understood.
Expression of the stem cell-specific protein Oct-3/4,
one of the earliest transcription factors expressed in
the embryo, regulates pluripotency of ES cells. Oct-3/4
encoded by Pou5f1 belongs to the family of POU (Pit
Oct Unc) genes. It regulates gene transcription by bind-
ing to DNA octamer motifs ATGCAAAT. Strong evidence
has implicated Oct-3/4 in embryogenesis and cell differ-
entiation. Oct-3/4 is developmentally regulated. In the
early embryo, the homeobox-containing gene Pou5f1
is expressed in the inner cell mass, and downregulated
in the trophoectoderm (Pesce and Scholer, 2001). Oct-
3/4-deficient embryos form the blastocyst, but the inter-
nal cells of the prospective ICM are unable to produce
extraembryonic endoderm or other differentiated deriv-
atives and rather become diverted into the trophoecto-
derm lineage (Nichols et al., 1998). However, downregu-
lation of Oct-3/4 is not necessary to allow ES cells to
differentiate. Indeed, forced and long-term expression
of the transcription factor does not relieve the depen-
dence of cells upon leukemia inhibitory factor (LIF),
and cells differentiate similarly to the parental cells
when LIF is removed (Niwa et al., 2000). The level of
Oct-3/4 expression in ES cells is crucial to maintain their
stem cell characteristics, including pluripotency. Trans-
gene-mediated overexpression of Oct-3/4 of less than
2-fold triggers within a week differentiation of cells into
primitive endoderm and mesoderm (Niwa et al., 2000).
Whether this phenomenon does require a long-term
and sustained increase in Oct-3/4 and how such an up-
regulation could occur in the early embryo in a physio-
logical dependent manner is unknown. Interestingly,
fate mapping experiments have uncovered that cardiac
progenitors, first located in the posterior lateral region of
the epiblast, still express the POU transcription factor
Oct-3/4 at early gastrulation (Tam and Schoenwolf,
1999). Oct-3/4 is downregulated in the epiblast of the
TGFb-related factor nodal-deficient mice (Brennan
et al., 2001). A similar downregulation was observed in
transgenic mice lacking Smad2 (Waldrip et al., 1998),
a signaling protein which functions downstream of the
TGFb receptor (Derynck and Zhang, 2003). This was ac-
companied by the absence of the mesodermal marker
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536Brachyury (Waldrip et al., 1998). This suggests that
a TGFb-related signaling pathway is required to main-
tain Oct-3/4 expression in the early embryo and that
Oct-3/4 may be required for early mesodermal and car-
diac cell commitment in the embryo.
ES cells faithfully recapitulate the early stages of car-
diac cell commitment and differentiation (Leahy et al.,
1999; Loebel et al., 2003). We have previously shown
that ES cells can be committed toward a cardiac lineage
by growth factors belonging to the TGFb superfamily
(Behfar et al., 2002; Mery et al., 2003), factors known to
be cardiogenic in the early embryo (Kinder et al., 2001;
Ladd et al., 1998). Altogether, these findings prompted
us to investigate whether Oct-3/4 was involved in a phys-
iological dependent manner in early commitment of the
epiblast and ES cells toward mesodermal and cardiac
lineages. Herein, we provide evidence in vivo for a role
of Oct-3/4 in mesodermal commitment of the epiblast
of mouse embryos. We further show that transient
Oct-3/4 upregulation is a prerequisite for Smad-medi-
ated and TGFb-induced expression of mesodermal
and cardiac specific genes and for both proper cardiac
differentiation of ES cells in vitro and early cardiac devel-
opment in vivo. Our study provides evidence in vitro and
in vivo for a gene dosage function of Oct-3/4 in stem cell
differentiation.
Results
Induction of Oct-3/4 above Its Basal Value Induces
Expression of Cardiac Mesodermal Genes
in ES Cells
Niwa et al. (2000) reported that elevated expression of
Oct-3/4 for 4 days directs the fate of ES cells toward en-
domesoderm. To revisit this concept in a quantitative
manner, we first used the Tet-Off ZHTc6 ES cell clone
(Niwa et al., 2000) to increase basal level of expression
of Oct-3/4 by removing tetracycline from the culture me-
dium of ES cells for 2 days. Oct-3/4 expression went up
by 3-fold both at the level of mRNA (Figure 1A) and pro-
tein (Figure 1A, inset). Oct-3/4 upregulation triggered ex-
pression of mesodermal (i.e., Brachyury) and cardiac
mesodermal genes (Tbx6, Mesp1). Mesodermal com-
mitment of cells was further translated into cardiac
specification of ES cells, as genes encoding cardiac
transcription factors (Tbx5, Mef2c, Nkx2.5, myocardin)
or constitutive genes (a-actin) were also upregulated in
Oct-3/4-overexpressing cells. Expression of Isl-1, a
marker of the secondary heart field (Buckingham et al.,
2005), was not changed, in line with the observation in
human ES cells that Oct-4, SOX2, and nanog cooccu-
pied its gene found in a transcriptionally inactive state
(Boyer et al., 2005). Expression of gene markers of vis-
ceral (a-feto protein), parietal (tissue plasminogen acti-
vator; tPA), endoderm, or markers of neuronal (nestin)
or hematopoietic (Tal1) cell lineages were not signifi-
cantly affected by Oct-3/4 upregulation (Figure 1A).
Cells were then allowed to differentiate within embry-
oid bodies. Monitoring of gene expression in day 5
embryoid bodies (EBs), a three-dimensional structure
comprising the three embryonic layers, revealed an in-
crease in mesodermal cells and, more specifically, car-
diac progenitors expressing Tbx6, Tbx5, and Mesp1,
as well as Mef2c, Nkx2.5, myocardin, and a-actin with-out any change in Isl-1 expression. Differentiation of he-
matopoietic, endodermal, or neuronal cell lineages was
not favored by Oct-3/4 overexpression, as revealed by
the lack of induction of Tal1, a-feto protein, tPA, or nes-
tin genes (Figure 1B). Cardiac commitment of ES cells
following Oct-3/4 upregulation was translated in a full
program of cardiogenesis as shown by a 4.2 6 0.2 fold
(n = 3) increase in actinin-expressing cells in day 12
EBs (Figure 1C).
Upregulation of Oct-3/4 mRNA in Spontaneous and
TGFb-Induced Cardiac Specification of ES Cells
To gain more insight into physiological regulation of Oct-
3/4 expression and its role in mesodermal cell commit-
ment, we used a wild-type CGR8 ES cell line, derived
from the inner cell mass of the blastocysts (Smith,
1991), a model that recapitulates the early stages of car-
diac differentiation. TGFb is one of the first factors to
Figure 1. Induced Expression of Oct-3/4 Triggers Expression of Me-
sodermal and Cardiac Genes
(A) The ZHTc6 ES cell clone was propagated for two passages in the
presence of 100 ng/ml tetracycline (Tc) and LIF. Tc was then re-
moved from the medium for 48 hr to allow for overexpression of
Oct-3/4. RNA was then extracted from cells and used for real-time
PCR of a series of endodermal and ectodermal (white), endomeso-
dermal (orange), mesodermal (blue), and cardiac specific genes
(green). Data were normalized to tubulin expression and presented
as a fold increase versus basal Oct-3/4 mRNA level in ES cells main-
tained in the presence of Tc. The inset shows anti-Oct-3/4 and anti-
tubulin Western blots of proteins extracted from control or induced
ZHTc6 cells.
(B) EBs were generated from ES cells overexpressing Oct-4 or not.
EBs were collected at day 5 for real-time PCR.
(C) Some EBs were collected at day 12 and fixed for immunostaining
using an anti-sarcomeric actinin antibody.
The data are expressed as the average6 SEM of six experiments. *,
significantly different from control; p% 0.001.
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537Figure 2. TGFb Upregulates Oct-3/4 mRNA and Protein in ES Cells
(A) CGR8 ES cells were treated for 24 hr with 5 ng/ml TGFb. RNA was
extracted and used for real-time PCR. Data were normalized to tubu-
lin expression and presented as a fold increase versus Oct-3/4
mRNA level in mock ES cells. The data are expressed as the average
6 SEM of five to eight experiments. The inset shows anti-Oct-3/4
and anti-tubulin Western blots of proteins extracted from control
or TGFb-treated cells.
(B) Basal Oct-3/4 expression in Oct-3/4 siRNA-expressing cells
monitored by real-time quantitative PCR. Data were normalized to
tubulin expression and expressed as a percentage of control (i.e.,
cells transfected with an empty pcDNA3.1 vector). Cells were also
LIF starved for 96 hr and used as a reference of the lowest Oct-3/4
levels expressed in ES cells differentiated to trophoectodermal cells.
(C) The upper panels show mock ES cells (mock, transfected with an
empty pcDNA3.1 vector) or ES cells expressing a control siRNA (see
Experimental Procedures), and the lower panels show cells express-
ing the Oct-3/4 antisense (AS) or the Oct-3/4 siRNA, stained with pri-
mary anti-Oct-3/4 and anti-SSEA1 antibodies and secondary blue
Alexa 360-conjugated anti-rabbit IgG and red Alexa 546-conjugated
anti-mouse IgG, respectively. Images were acquired simultaneously
at different wavelengths using an LSM510 confocal microscope (op-
tical section 1 mm).
(D) ES cells were transfected with pSuperOct4siRNA 12 hr prior to
TGFb addition. Some cells were collected; others were allowed to
differentiate within EBs and collected later at days 2 and 5. RNA
was then extracted from ES cells or EBs and reverse transcribed.
Real-time quantitative PCR was used to amplify Oct-3/4 mRNA.
Data were normalized to tubulin expression and presented as
a fold increase versus Oct-3/4 mRNA level in untreated ES cells.
The data are expressed as the average 6 SEM of five to eight
experiments. Nonstimulated cells were transfected with an emptyinduce cardiac myogenesis in the epiblast of the embryo
(Kinder et al., 2001; Ladd et al., 1998). We previously
showed that undifferentiated murine CGR8 ES cells cul-
tured without feeder cells respond to the endodermal
and cardiogenic factor TGFb1, increasing their propen-
sity to differentiate toward the mesodermal and cardiac
lineages (Behfar et al., 2002; Mery et al., 2003). Indeed,
undifferentiated CGR8 ES cells cultured in the absence
of feeder cells expressed both TGFb receptors I and II
to the same extent as day 2 EBs (see Figure S1 in Sup-
plemental Data available with this article online). A
gene chip approach also showed that the downstream
signaling components of TGFb receptors (i.e., Smad2
and 3) are expressed in undifferentiated ES cells (Ram-
alho-Santos et al., 2002; our unpublished data). Expres-
sion of Smad2/3 was detected by immunostaining of un-
differentiated CGR8 cells. The transcription factor was
mainly located in the cytosol (92% 6 3% intracytosolic
staining) of control cells and was translocated into the
nuclei following stimulation of cells with TGFb (95% 6
2% intranuclear staining) (Figure S1B). Nuclear localiza-
tion of Smad2/3 in TGFb-challenged cells was con-
firmed by observation of nuclei under transmitted light
and DNA staining with Hoechst (Figure S1, insets).
Thus, CGR8 ES cells feature a functional TGFb receptor
signaling pathway.
Cells treated for 24 hr with 5 ng/ml TGFb1 grew at the
same rate as nontreated cells, as revealed by the same
percentage of BrdU-positive cells in the two populations
(75% 6 5% versus 70% 6 5%, respectively). Further-
more, these cells remained undifferentiated, as shown
by sustained expression of both the SSEA1 antigen
and nanog (Figures S1C and S1D).
To mimic the scenario that is likely to occur in cells of
the epiblast bathed in LIF and surrounded by primitive
endoderm-secreting TGFb-related growth factors,
TGFb1 (5 ng/ml) was applied in the presence of LIF for
24 hr to undifferentiated ES cells. Such a treatment re-
sulted in a 3-fold increase in Oct-3/4 mRNAs and protein
content (Figure 2A). The transcriptional effect was sus-
tained and even more prominent in day 2 embryoid bod-
ies. Oct-3/4 mRNA content was four to five times higher
in EBs generated from TGFb-treated ES cells than in
control EBs. A slight increase in Oct-3/4 mRNA level
was also observed in day 2 EBs when compared to un-
differentiated ES cells, likely induced by TGFb or related
factors released from nascent endodermal cells. At day
5, Oct-3/4 was fully downregulated in EBs generated
from both control and TGFb-pretreated ES cells (Fig-
ure 2A). Nodal (10 ng/ml) as well as BMP2 (2.5 ng/ml)
exerted a similar upregulation of Oct-3/4. Nodal also
triggered expression of mesodermal (Tbx6) and cardiac
specific genes (Mef2c, Nkx2.5) (Figure S2).
To investigate the role of transient Oct-3/4 upregula-
tion during ES cell differentiation, we designed a series
of experiments to prevent this phenomenon without
affecting the pluripotency of ES cells. Oct-3/4 was
knocked down by transgene-mediated transient
expression of a specific antisense cDNA or small inter-
fering RNA (siRNA) (Kim et al., 2002). Vector-mediated
pcDNA3.1 plasmid or with a control siRNA (see sequence in
Experimental Procedures). *, significantly different from control;
p% 0.001.
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Oct-3/4 mRNA level (Figure 2B) down to 35% 6 6% of
control value and significantly and transiently decreased
expression of the protein (Figure 2C). Expression of a
cDNA antisense also dramatically and transiently
knocked down expression of the protein Oct-3/4 (Fig-
ure 2C). Expression of both Oct-3/4 siRNA and anti-
sense blunted TGFb-induced upregulation of Oct-3/4
mRNAs in both ES cells and EBs at day 2 (Figure 2D). Im-
portantly, these ES cells remained undifferentiated cells,
as shown by positive immunostaining with an anti-
SSEA1 antibody (Figure 2C). The effect of TGFb on ES
cells was not mediated by Oct-3/4 per se: TGFb in-
creased by 4-fold p21Waf1/Cip1 mRNA content in ES cells,
and this response was not affected in cells expressing
siRNA or Oct-3/4 antisense (4.5 6 0.4 fold increase in
mock cells, versus 5.3 6 0.4 and 5.2 6 0.4 in siRNA
and Oct-3/4 antisense-expressing cells, respectively;
n = 3).
TGFb-Induced Upregulation of Oct-3/4 Expression
Is Required for Mesodermal Commitment of ES Cells
We then asked whether TGFb–induced upregulation of
Oct-3/4 was a prerequisite for mesodermal commitment
of cells by the morphogen (Behfar et al., 2002). TGFb ap-
plied to undifferentiated ES cells in the presence of LIF
triggered a 4-fold increase in expression of the meso-
dermal specific transcription factor Brachyury (Fig-
ure 3A). This effect was sustained and more prominent
in day 2 EBs (Figure 3B). Expression in ES cells of an
Oct-3/4 siRNA or a cDNA antisense which knocked
down expression of Oct-3/4 mRNA and protein within
24 hr (Figure 2) repressed TGFb-triggered Brachyury ex-
pression in both undifferentiated ES cells (Figure 3A)
and EBs at day 2 (Figure 3B). Formation of EBs including
appearance of a layer of endodermal cells at the border
of EBs was not affected under any experimental condi-
tions used to disturb Oct-3/4 expression (Figure 3, left
inset). It should also be noted that downregulation of
Oct-3/4 was transient and not long enough to trigger
trophoectodermal differentiation of ES cells. Indeed,
Cdx2, a marker of proliferating trophoectodermal cells,
was never detected in ES cells under any experimental
conditions used to prevent Oct-3/4 upregulation by
TGFb (data not shown).
TGFb-Induced Upregulation of Oct-3/4 Expression
Is Specifically Required for Cardiac Commitment
of ES Cells
Upregulation of Oct-3/4 was further required to mediate
TGFb-induced upregulation of cardiac specific genes,
including Mef2c and Nkx2.5. TGFb increased by 8- and
3-fold in ES cells and by 3- and 4-fold in day 2 EBs the
content of mRNAs encoding Mef2c (Figure 4A) and
Nkx2.5 (Figure 4B), respectively. Under both experimen-
tal conditions designed to prevent Oct-3/4 upregulation
(i.e., cDNA antisense and siRNA), no transcriptional re-
sponse to the morphogen was observed in either ES
cells or day 2 EBs (Figures 4A and 4B). Indeed, neither
Nkx2.5 nor Mef2c mRNAs levels were increased upon
TGFb stimulation of ES cells. A control siRNA did not af-
fect terminal cardiac differentiation of ES cells, exclud-
ing any nonspecific effect of the siRNA approach.We further investigated whether the level of expres-
sion of Oct-3/4 modulated other differentiation path-
ways. Neither the level of mRNA encoding tPA, a specific
parietal endodermal marker, nor the mRNA encoding
a-fetoprotein, a marker of visceral endoderm, differed
in TGFb-treated ES cells or EBs as compared to
the equivalent populations of untreated cells. Neither
a-fetoprotein nor tPA expression was affected in ES
cells expressing Oct-3/4 cDNA antisense or an siRNA
(data not shown). Further, EBs generated from ES cells
expressing Oct-3/4 cDNA antisense or an siRNA nor-
mally differentiated into the three germ layers as illus-
trated in Figure S3. Expression of neuroectodermal,
epidermal, endodermal, and muscle genes or proteins
b3-tubulin, nestin, cytokeratin17 and Myf5, and albumin,
respectively, as well as the presence of adipocytes, was
normal in day 8 EBs generated from ES cells expressing
the Oct-3/4 antisense or siRNA. Furthermore, besides
muscle genes, genes expressed in other mesodermal
derivatives including the hematopoietic (Tal1 and
CD34), smooth muscle (SM actin), and endothelial
(ICAM) lineages were normally expressed in cells ex-
pressing the Oct-3/4 antisense or siRNA (Figure S3).
Similar data were found using another mouse ES cell
Figure 3. Transient Oct-3/4 Upregulation Is Required for TGFb-
Induced Mesodermal Commitment of ES Cells
(A) CGR8 ES cells were treated for 24 hr with 5 ng/ml TGFb. Cells
were transfected with pSuperOct4siRNA or pcDNAOct4-antisense
(AS) 12 hr prior to TGFb addition. Some cells were collected at day
0 (D0).
(B) Others were allowed to differentiate within EBs and collected
later at day 2 (D2). Real-time quantitative PCR was used to amplify
Brachyury mRNA. Data normalized to tubulin expression are ex-
pressed as a fold increase in Brachyury expression versus untreated
ES cells and are the average6 SEM from five experiments. Pictures
of day 2 EBs are displayed in the left inset.
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found in CGR8 cells, an siRNA-mediated inhibition of
Oct-3/4 blunted TGFb-induced upregulation of meso-
dermal (Tbx6, Brachyury) or cardiac genes (Nkx2.5,
Mef2c) (Figure S4A) and further cardiac cell differentia-
tion as visualized by actinin staining of EBs
(Figure S4B). Altogether, we conclude that transient
Oct-3/4 is specifically required for TGFb-induced car-
diac commitment of ES cells.
TGFb-Induced Early Upregulation of Oct-3/4
Expression Is Required for Cardiac Differentiation
of ES Cells
Next, we sought to determine whether early and tran-
sient TGFb-induced upregulation of Oct-3/4 was re-
quired to translate cardiac cell commitment into a full
differentiation program. Cells were allowed for 12 days
to fully differentiate to cardiomyocytes within embryoid
bodies. Anti-sarcomeric actinin and anti-b-myosin
heavy chain staining of EBs revealed the presence of
an increased number of cardiomyocytes when cells
were pretreated with TGFb as compared to EBs gener-
ated from nontreated cells (Figure 5A). Actinin-positive
areas within EBs increased from 18% 6 2% to 43% 6
7% of the mesodermal area of EBs (Behfar et al.,
2002). However, under all experimental conditions
used to repress or to knock down expression of
Figure 4. Transient Oct-3/4 Upregulation Is Required for TGFb-
Induced Cardiac Commitment of ES Cells
CGR8 ES cells were treated for 24 hr with 5 ng/ml TGFb. ES cells
were transfected with pSuperOct4siRNA or pcDNAOct4-antisense
(AS) 12 hr prior to TGFb addition. Some cells were collected at day
0 (D0); others were allowed to differentiate within EBs and collected
later at day 2 (D2).
Real-time quantitative PCR was used to amplify Mef2c (A) and
Nkx2.5 mRNAs (B). Data were normalized to tubulin expression
and presented as a fold increase versus the level of the gene of in-
terest in untreated ES cells. The data are expressed as the average
6 SEM of five experiments.Oct-3/4 (i.e., Oct-3/4 antisense and siRNA expression
in ES cells), the enhancing effect of the morphogen on
cardiogenesis was not observed (Figure 5B) and acti-
nin-labeled areas went down to 3% 6 1% and 5% 6
2% of the mesodermal area of EBs, respectively.
When transient upregulation of Oct-3/4 was blocked,
a few cardiomyocytes could be visualized in EBs and
the number of cardiomyocytes never further increased
with time. Furthermore, observation of EBs at high mag-
nification revealed that the formation of sarcomeric units
in the remaining cardiomyocytes was impaired, sug-
gesting a severe block in the cardiac differentiation pro-
cess (Figure 5B).
Smad2, but Not Smad3, Mediates TGFb-Induced
Upregulation of Oct-3/4
Next, we addressed the question of the signaling path-
ways that mediate the regulatory effect of TGFb on
expression of Oct-3/4 in ES cells. Signaling by TGFb is
mediated by effectors, namely the Smad proteins. The
morphogen also activates the MAPK pathways (ERK1,
2, or p38) (Derynck and Zhang, 2003; Massague, 2000).
ES cells were first treated with 10 mM SB202186 or
Figure 5. Transient Oct-3/4 Upregulation Is Required for TGFb-
Induced Improvement in Cardiac Differentiation of ES Cells
(A) CGR8 ES cells were treated for 24 hr with 5 ng/ml TGFb.
(B) ES cells were transfected with pSuperOct4siRNA or pcDNAOct4-
antisense (AS) 12 hr prior to TGFb addition. Cells were allowed to
differentiate within EBs for 12 days. EBs were immunostained with
an anti-sarcomeric actinin or b-MHC antibody and observed by con-
focal microscopy using a 103 or 633 objective. The images are rep-
resentative of three to five separate experiments.
Developmental Cell
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TGFb-Induced Upregulation of Oct-3/4 and
Cardiac Commitment of ES Cells
ES cell lines expressing a dominant-negative
mutant of Smad2 (Smad2DSSMS) or Smad3
(Smad3DSSVS) were generated and checked
for expression of the mutants using an anti-
flag antibody to immunoprecipitate the
Smad mutants and anti-Smad2/3 antibody
to reveal the blot ([B], inset). Cells were then
treated for 24 hr with 5 ng/ml TGFb and al-
lowed to differentiate for 12 days within EBs.
(A) Day 2 EBs generated from Smad2DSSMS-
expressing ES cells treated or not with TGFb
were imaged by phase contrast microscopy.
(B) Real-time quantitative PCR was used to
amplify Oct-3/4, Brachyury, Mef2c, and
Nkx2.5 mRNAs in ES cells. Data were normal-
ized to tubulin expression and presented as
a fold increase versus the level of the gene
of interest in untreated Smad2DSSMS-
expressing ES cells. The data are expressed
as the average 6 SEM of three experiments.
(C) Cardiomyocytes were visualized in day 12
EBs by anti-sarcomeric actinin immunostain-
ing and observed by confocal microscopy
using a 103 or 633 objective.
(D) Day 2 EBs generated from Smad3DSSVS-
expressing ES cells treated or not with TGFb
were imaged by phase contrast microscopy.
(E) Real-time quantitative PCR was used to
amplify Oct-3/4, Brachyury, Mef2c, and
Nkx2.5 mRNAs in ES cells. Data were normal-
ized to tubulin expression and presented as
a fold increase versus the level of the gene
of interest in untreated Smad3DSSVS-
expressing ES cells. The data are expressed
as the average 6 SEM of three experiments.
(F) Cardiomyocytes were visualized in day 12
EBs by anti-sarcomeric actinin immunostain-
ing and observed by confocal microscopy
using a 103 or 633 objective.
(G) ES cells were transiently transfected with
Smad2 or Smad3 siRNA and checked for
expression of Smad mRNA by real-time
PCR (n = 2). ES cells were then stimulated
with 5 ng/ml TGFb 24 hr later.
(H–J) Expression of Oct-3/4 (H), Brachyury (I), and Mef2c (J) mRNA was monitored by real-time PCR. Data were normalized to tubulin expression
and presented as an average (mean 6 SEM, n = 3) of a fold increase versus the level of the gene of interest in mock ES cells.
(K) ES cells were stimulated for 24 hr with 5 ng/ml TGFb, fixed, crosslinked, lysed, and used for ChIP using an anti-Smad4 antibody. DNA was
amplified in real-time PCR. The product was identified by its melting curve, its size on the gel (inset), and by sequencing. The quantification was
performed by calculating the area under the melting curve. The figure is representative of three experiments. *, significantly different from control;
p% 0.001.U0126 prior to TGFb stimulation. Neither the ERK1, 2,
nor the p38 inhibitor affected upregulation of Oct-3/4
by the morphogen (data not shown). Interestingly, Oct-
3/4 is downregulated in the epiblast of Smad2-deficient
mice (Waldrip et al., 1998). To specifically prevent
activation of Smad2, an ES cell line expressing a
dominant-negative mutant of Smad2 (Choy et al.,
2000) was generated. Cells expressing the Smad2 mu-
tant (Smad2DSSMS) aggregated normally in EBs (Fig-
ure 6A). However, TGFb did not result in upregulation
of Oct-3/4 mRNA in undifferentiated ES cells expressing
the mutated Smad (Figure 6B). TGFb-induced expres-
sion of Brachyury or cardiac specific genes (i.e., Mef2c
and Nkx2.5) was not observed in Smad2DSSMS-
expressing ES cells (Figure 6B). In line with these find-
ings, the number of ES cell-derived actinin-positive car-
diomyocytes was low (5% 6 2% of the mesodermalarea of EBs) and did not increase in response to pre-
treatment of ES cells with TGFb (Figure 6C). In contrast,
the TGFb transcriptional response with regard to Bra-
chyury, Nkx2.5, Mef2c, and Oct-3/4 gene expression in
embryoid bodies expressing a dominant-negative mu-
tant of Smad3 (Smad3DSSVS) (Figure 6D) to an extent
similar to Smad2DSSMS (inset, Figure 6B) was con-
served (Figure 6E). The genetic response of cells to
BMP2, which functions through Smads 1, 5, and 8 (Der-
ynck and Zhang, 2003), was not affected in cells ex-
pressing the dominant-negative mutants of Smad2 or
3. BMP2 (2.5 ng/ml) applied to undifferentiated ES cells
expressing the dominant-negative mutants of Smad2 or
3 increased within 24 hr by 3.2 6 0.1, 6 6 0.5, and 3.5 6
0.5 fold Brachyury, Mef2c, and Nkx2.5 mRNA levels,
respectively, as previously reported (Behfar et al.,
2002). In line with normal expression of cardiac markers
Role of Oct-3/4 in Early Cardiogenesis
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featuring abundant cardiomyocytes with regular myofi-
brillogenesis were observed only after TGFb treatment
of ES cells prior to differentiation (Figure 6F).
The mode of action of Smad dominant-negative mu-
tants (Choy et al., 2000) may, however, call for caution
as to their true specificity. To further discriminate be-
tween the role of Smad2 and Smad3 in TGFb-induced
regulation of Oct-3/4 expression, ES cells were trans-
fected with siRNAs designed to specifically knock
down Smad expression in mink cells (Major and Jones,
2004). Expression of Smad siRNAs in ES cells decreased
by 50% and 75% expression of Smad2 and Smad3
mRNAs, respectively (Figure 6G). In cells expressing
Smad2 siRNA but not Smad3 siRNA, the transcriptional
response to TGFb was blunt. Oct-3/4 upregulation was
completely abolished (Figure 6H). TGFb-triggered upre-
gulation of both Mef2c and Brachyury was fully inhibited
by Smad2 siRNA, while a partial response remained in
cells expressing Smad3 siRNA (Figures 6I and 6J).
Smad4 Binds Oct-3/4 Promoter in ES Cells
Smad4 integrates signals from regulatory Smads (i.e.,
Smad2/3, 1/5/8) and binds DNA. It is an essential factor
for mesoderm induction (Yang et al., 1998). In silico
analysis of the Oct-3/4 promoter (GenBank accession
number AJ297528.1jMMU297528) identifies two Smad
consensus sequences, one upstream of the proximal
and one upstream of the distal enhancer. To experimen-
tally determine whether Smad4 could recognize these
sequences in Oct-3/4 promoter, we used the chromatin
immunoprecipitation (ChIP) assay. ES cells were stimu-
lated for 24 hr with TGFb and chromatin was immuno-
precipitated with an anti-Smad4 antibody. Real-time
PCR using primers matching proximal Oct-3/4 promoter
revealed that DNA fragments containing the Smad4
elements were enriched up to 5-fold when immuno-
precipitated with the anti-Smad4 antibody in nuclear ex-
tracts prepared from TGFb-stimulated cells (Figure 6K).
Primers matching the distal enhancer did not amplify
any product (data not shown).
Oct-3/4 Is Required In Vivo for Mesodermal
Commitment of the Epiblast
Fate mapping experiments have shown that cardiac
progenitors, first located in the posterior lateral region
of the epiblast, still express the POU transcription factor
Oct-3/4 at early gastrulation (Tam and Schoenwolf,
1999). We first tested expression of Oct-3/4 in the
course of differentiation of blastocysts ex vivo. Blasto-
cysts were cultured for 5 days in the presence of the
stem cell factor to favor their attachment to the culture
dish and further development toward the epiblast (Mit-
sunari et al., 1999). Figure 7A shows that Oct-3/4 tran-
siently increased up to day 3 of differentiation of the
blastocyst and then decreased. Next, we tested in vivo
whether Oct-3/4 was required for mesodermal commit-
ment of cells of the epiblast prior to gastrulation. Blasto-
cysts obtained at E3.5 were injected with an Oct-3/4
siRNA bound to the DNA/RNA delivery peptide MPG2
or with MPG2 alone or neutral siRNA bound to MPG2.
We first checked that microinjection of MPG2, the
DNA/RNA delivery peptide per se or bound to a neutral
siRNA, did not affect the viability of blastocysts. Tosuch an aim, MPG2-injected blastocysts were reim-
planted into pseudopregnant mice. These blastocysts
developed normally (Figure 7D) up to the term of the
gestation. In blastocysts injected with the Oct-3/4
siRNA, expression of Oct-3/4, but not of nanog, was sig-
nificantly downregulated both at the level of mRNA and
protein as revealed by real-time PCR and immunofluo-
rescence, respectively (Figures 7B and 7C) when com-
pared to the extent of expression found in blastocysts
injected with the gene delivery peptide MPG2 alone, or
bound to a neutral siRNA. Expression of a-fetoprotein,
an early endodermal marker, was not significantly af-
fected. Expression of two mesodermal genes expressed
early in the mesodermal lineages of the epiblast, Bra-
chyury (Yamaguchi et al., 1999) and Tbx6, both respon-
sive to stimulation by members of the TGFb superfamily
(Chapman et al., 1996; Szeto and Kimelman, 2004) and
downstream of Oct-4 (Figure 1), were strongly ex-
pressed in control blastocysts kept for 5 days in culture,
whereas they were poorly expressed in blastocysts in-
jected with the Oct-3/4 siRNA (Figure 7C).
Oct-3/4 Expression in the LateBlastocyst Is Required
In Vivo for Heart Development
We next addressed the question of whether blunting
Oct-3/4 upregulation during early development of blas-
tocysts affected cardiac morphogenesis later on. Blas-
tocysts injected with Oct-3/4 siRNA were reimplanted
into pseudopregnant mice. Fifty percent of embryos
aborted by E12.5. Forty percent of embryos developed
with a significant delay. At E9.5, surviving embryos
were smaller and delayed in their development (14 6 2
somites, n = 25) than the ones derived from blastocysts
injected with the MPG2 vector (22 6 1 somites, n = 26)
alone or bound to an irrelevant siRNA (Figures 7D and
7E). A very few embryos developed up to birth. The
poor rate of birth and significant delay in development
might be attributed to defects in heart morphogenesis.
Indeed, at E9.5, in situ hybridization revealed weaker
Nkx2.5 and a-actin expression in embryos derived
from Oct-4 knockout blastocysts than in the ones de-
rived from blastocysts injected with MPG2 alone
(Figure 7F). Myosin heavy chain staining also showed
that trabeculation is missing in the hearts of Oct-4
knockout embryos (Figure 7G).
At E12.5, hearts were fully formed in embryos derived
from blastocysts injected with MPG2. In embryos devel-
oped from Oct-3/4 siRNA-injected blastocysts the ven-
tricular walls were much thinner, indicating a significant
impairment in myocardial cell determination. Trabecula-
tion of the ventricle was reduced and myofibrillogenesis
was impaired in myocardial fibers of embryos derived
from Oct-3/4 siRNA-injected blastocysts (Figure 7H).
As a likely consequence, at E12.5, growth delay in siRNA
Oct-3/4 embryos was even more dramatic (Figure S5).
Discussion
The embryonic stem cell transcription factor Oct-3/4
was qualified as a pluripotency gatekeeper (Nichols
et al., 1998) but also appeared to direct cell fate toward
primitive endoderm and mesoderm (Niwa et al., 2000) in
the presence of LIF or ectoderm in the absence of LIF
and BMPs (Shimozaki et al., 2003). Herein, we show
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542Figure 7. In Vivo Requirement of Oct-3/4 in
Mesodermal Commitment of the Epiblast
and Heart Morphogenesis
(A) Blastocysts (stage E4.5) were flushed out
from the uterus of pregnant mice. Blastocysts
were then cultured for 5 days in the presence
of 100 ng/ml stem cell factor prior to RNA ex-
traction and real-time PCR of Oct-3/4.
(B) Blastocysts injected with MPG2 alone
(control) or with Oct-3/4 siRNA were immuno-
stained with an anti-Oct-3/4 antibody.
(C) Expression in control (MPG2-injected)
and Oct-3/4 siRNA-injected blastocysts of
Oct-3/4, nanog, a-feto protein (a-FP), Bra-
chyury, and Tbx6 mRNAs was monitored by
real-time PCR. Data were normalized to tubu-
lin expression and presented as a percentage
(mean 6 SEM, n = 3 experiments, six to eight
blastocysts) of the level of the gene of interest
in MPG2-injected blastocysts.
(D) Blastocysts were injected with the vector
MPG2 or with MPG2 bound to Oct-3/4 siRNA
and reimplanted into pseudopregnant mice.
Embryos were collected at different stages
of development from E6.5 to E12.5. Many
embryos aborted by E9.5. Some featured
a severe delay in development as illustrated.
(E) Bar graph summarizing data from 125
embryos.
(F and G) Sections of E9.5 embryos were
probed with Nkx2.5 and a-actin probes (a,
atrium; v, ventricle) (F) and immunostained
with anti-b-MHC antibody (G).
(H) Sections of E12.5 embryos were immuno-
stained with an anti-sarcomeric actinin anti-
body and the heart was visualized by confo-
cal microscopy. The arrows indicate the
ventricular wall that is thinner in embryos
generated from Oct-3/4 siRNA-injected blas-
tocysts than in controls injected with the vec-
tor MPG2 alone. The images at the center of
the panel show a high-magnification image
of myocardial fibers in the ventricular wall.
Note the regular sarcomeric structures in
the control and loose myofibrils in Oct-3/4
siRNA embryos.that in the presence of LIF and a cardiogenic factor, Oct-
3/4 upregulation triggers cardiac specification of stem
cells and the epiblast.
Upregulation of Oct-3/4 Specifically Directs Stem
Cell Fate toward a Cardiac Lineage
We first uncovered that transgene-mediated 3-fold in-
crease in Oct-3/4 expression for 48 hr, an event that
physiologically occurs with the same time course in
blastocysts and embryoid bodies, induces expression
of mesodermal and cardiac specific genes but not of en-
dodermal or ectodermal genes in both ES cells and fur-
ther in EBs. This extends in a more quantitative and
timely manner the findings of Niwa and collaborators
(Niwa et al., 2000). They further suggest that quantitative
expression of the POU factor in the presence of LIF
drives ES cells toward a cardiac lineage.
The present study was then aimed at understanding
whether a cardiogenic morphogen acting in early em-
bryogenesis regulates Oct-3/4 expression and, if so,
whether such a phenomenon plays a role in mesodermal
commitment of ES cells. Our findings provide evidence
that a short and transient upregulation of Oct-3/4 iscommonly observed at early time points postdifferentia-
tion both in EBs and blastocysts that feature a nascent
endoderm secreting TGFb-related factors (i.e., two first
days, Figures 2A and 7). Such Oct-3/4 upregulation is
significantly increased by morphogens, TGFb, BMP2,
or nodal, inducers of cardiac mesoderm.
Importantly, TGFb-treated ES cells remained in an un-
differentiated state, as shown by anti-SSEA1 immunos-
taining, sustained nanog expression, and a rapid rate of
growth (Savatier et al., 1996). This excludes the hypoth-
esis that TGFb-responsive ES cells, expressing both
subtypes I and II of TGFb receptors and their intracellu-
lar signaling components (i.e., Smad2/3), represent
a specific population of predifferentiated cells. Major
findings demonstrate that this transient event is pivotal
for the induction of the mesodermal marker Brachyury,
and further of cardiac markers Nkx2.5 and Mef2c. In-
deed, specific knockdown of Oct-3/4 expression using
silencing RNA or a cDNA antisense dramatically blunted
the effect of TGFb on cardiac commitment of ES cells
while preserving their undifferentiated state. This latter
point was ascertained by positive SSEA1 staining as
well as by upregulation of p21Waf1/Cip1, a well-known
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2000). Altogether, these findings demonstrate that a
transient Oct-3/4 upregulation mediates cardiac com-
mitment of ES cells. Transgene-mediated long-term
overexpression of Oct-3/4 also causes differentiation
of ES cells toward primitive endoderm (Niwa et al.,
2002). Similarly, in zebrafish, expression of Spg, the or-
tholog of Oct-3/4, is required for commitment of meso-
endodermal cells toward endoderm (Lunde et al.,
2004; Reim et al., 2004). Although TGFb upregulates
Oct-3/4 expression only in a transient manner, one
may argue that cardiac cell commitment is consecutive
to extraembryonic endodermal differentiation leading to
a paracrine secretion of TGFb or related factors. This hy-
pothesis is, however, unlikely, as expression of a domi-
nant-negative mutant and an siRNA of Smad2 which
blocked activation of both endogenous (i.e., secreted
by nascent endoderm in day 2 EBs) and exogenous
(i.e., added to the culture medium) TGFb receptor signal-
ing cascade fully prevented upregulation of both Oct-3/
4 and cardiac genes following cell stimulation with the
morphogen. Furthermore, no significant induction of en-
dodermal markers (i.e., tPA, a-feto protein) was ob-
served under stimulation of cells for 24 hr with TGFb
(data not shown) or in transgene-induced overexpres-
sion of Oct-3/4 (Figures 1A and 1B). Similarly, a-feto pro-
tein was normally expressed in blastocysts in which
expression of Oct-3/4 was knocked down by an siRNA.
In fact, TGFb-induced upregulation of Oct-3/4 is spe-
cifically required to direct ES cells toward a cardiogenic
fate. Indeed, transient knockdown of Oct-3/4 protein
(i.e., using an Oct-3/4 antisense and an siRNA) did not
affect other differentiation pathways including ectoder-
mal, mesodermal, and endodermal cell lineages, as
shown by normal generation of the three embryonic
layers in EBs as well as expression of specific neuronal
(nestin), epidermal (cytokeratin17), endothelial (ICAM),
hematopoietic (Tal1), or muscle markers (smooth mus-
cle actin and Myf5). Neuronal, liver, adipose, and hema-
topoietic cells were present to a similar extent in EBs
generated from Oct-4 knocked down ES cells as in
EBs generated from wild-type cells. Altogether, these
findings further demonstrate that ES cell pluripotency
was fully preserved even after inhibition of Oct-3/4 upre-
gulation by expression of Oct-3/4 antisense or Oct-3/4
siRNA.
Target genes of Oct-3/4 still have to be characterized
more for a better understanding of the physiological
mechanism underlying TGFb-induced cardiac commit-
ment of ES cells. It has, however, been reported that
the promoter of lefty, a factor which antagonizes the
function of TGFb superfamily members, includes an
Oct-3/4 enhancer element (Niwa et al., 2002). This may
appear as contradictory with our findings. Rather, this
pathway may serve as a negative feedback to balance
ES cell differentiation toward the three embryonic
germ layers. Target genes of Oct-3/4 shared by Sox2
and nanog were recently identified in both mouse
(Chew et al., 2005; Kuroda et al., 2005; Rodda et al.,
2005) and hESCs under experimental conditions re-
quired to maintain pluripotency of the cells (Boyer
et al., 2005). More specifically, Chew et al. (2005) discov-
ered a regulation of Oct-3/4 and Sox transcription by
each other. Upregulation of Oct-3/4 might be the wayfor the transcription factor to exit this self-reinforcing
autoregulatory loop to target other genes involved in
cell differentiation. The search for new targets when
Oct-3/4 is upregulated would thus be very helpful to bet-
ter comprehend the transcriptional network underlying
cardiac specification of ES cells.
The Smad Pathway Mediates TGFb-Induced
Oct-3/4 Upregulation
Another important question raised by our findings is the
intracellular signaling pathway of the TGFb receptor
which mediates the effect of the morphogen on Oct-3/4
upregulation. TGFb activates both ERK and p38 as
well as the Smad pathways (Derynck and Zhang, 2003;
Massague, 2000). ERK and p38 inhibitors were without
effects on this event, rather pointing to a Smad-regu-
lated pathway. Indeed, a dominant-negative mutant of
Smad2 (Smad2SSMS) and a Smad2 siRNA but not a
dominant-negative mutant (Smad3SSVS) (Choy et al.,
2000) or a Smad3 siRNA fully prevented regulation of
Oct-3/4 by TGFb. This finding is in line with the observa-
tion that in Smad22/2 (Waldrip et al., 1998) and nodal2/2
embryos (Brennan et al., 2001), the level of Oct-3/4 in the
epiblast is low and transient expression of Brachyury by
nascent mesoderm is missing in Smad2-deficient em-
bryos (Waldrip et al., 1998), while Smad3-deficient
mice develop to term (Datto et al., 1999; Yang et al.,
1999; Zhu et al., 1998). The specific regulation of Oct-
3/4 by Smad2 further supports the idea that Smad2
and Smad3 feature different targets and respond to spe-
cific upstream regulatory pathways (Felici et al., 2003;
Liu et al., 2004; Remy et al., 2004; Ten Dijke and Hill,
2004) as early as in the blastocyst stage. Such a
Smad2-dependent regulation might also be the conse-
quence of activation of a specific pool of TGFb receptors
(Ten Dijke and Hill, 2004). However, although Smad2
siRNA fully blunted TGFb-induced increase in mesoder-
mal (Brachyury) and cardiac genes (Mef2c), Smad3
siRNA also partially prevented this transcriptional
response. This suggests that Smad3 may act as an am-
plifier of the Smad2 signaling pathway, pointing to
a combinatorial role of Smad2 and Smad3 in mesoder-
mal and cardiac specification of ES cells as recently pro-
posed in mouse embryos (Dunn et al., 2004). Oct-3/4
transcription is likely to be directly regulated by the
Smad pathway, as Smad4 is capable of binding the
proximal enhancer of Oct-3/4 promoter upon cell stimu-
lation with TGFb (Figure 6).This further points to the role
of Oct-3/4 in cardiac mesodermal specification of ES
cells. Furthermore, our data bring a physiological signif-
icance to the fact that Oct-3/4 promoter (Nordhoff et al.,
2001) features several GTCT/AGAC potential Smad
binding sites (Johnson et al., 1999; Zawel et al., 1998), in-
cluding a tandem of these sequences 27 bases up-
stream of a GATA (GATAA) site. This adds to previous
findings implicating POU domain proteins in BMP sig-
naling pathways (Certel et al., 2000; Oren et al., 2005).
Our data further indicate that the effect of BMP on
self-renewal of ES cells (Ying et al., 2003), not shared
by TGFb, is not mediated by Smads. However, whether
Oct-3/4 exerts its action alone or activates cardiac
specific genes through cooperation with other tran-
scription factors (Molinari et al., 2004) is still question-
able. The POU factor may also participate in processes
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loci of specific cardiac genes. This is the subject of
ongoing investigation.
In Vivo Role of Oct-3/4 in Mesodermal Specification
of the Blastocyst
Our study extends beyond the stem cell field and dem-
onstrates that Oct-3/4 level is critical to direct the fate
of the inner cell mass in the blastocyst. Blastocysts de-
ficient in Oct-3/4 did not express the mesodermal tran-
scription factors Brachyury and Tbx6, as observed in
Smad22/2 (Waldrip et al., 1998) and nodal2/2 (Brennan
et al., 2001) blastocysts, also lacking Oct-3/4. This
strongly points to a role of Oct-3/4 in mesodermal com-
mitment of the epiblast, in vivo in mouse embryos. Fur-
thermore, blastocysts deficient in Oct-3/4 develop in
poorly viable embryos featuring defects in cardiac mor-
phogenesis. Myocardial deficiency (i.e., lack of trabecu-
lation) suggests a limitation in recruitment of cardiac
progenitors and/or in cardioblast proliferation at mid-
gestation to generate trabeculae. This might be at the
origin of impairment in the whole process of develop-
ment as already well documented from mice deficient in
cardiogenic factors or cardiac genes (Chen et al., 2004;
Niu et al., 2005; Shin et al., 2002), as cardiac function is
required at midgestation to provide the embryo with
oxygen and nutriments. This suggests that a gene dos-
age of Oct-3/4 may mark out early cardiac progenitors.
In embryogenesis, stem or progenitor cells respond to
threshold concentrations of morphogens to be commit-
ted to specific cell lineages. The specificity of the re-
sponse depends upon the number of occupied morpho-
gen receptors and might occur at the level of the
promoter of the target gene through two mechanisms.
Two separate genes may be turned on by two different
concentrations of the transcription factors depending
on the affinity of their promoter for the transcription fac-
tor. Alternatively but not exclusively, a repressor or an
enhancer of the gene promoter may be recruited and
may bind one but not the other gene promoter (Ashe
et al., 2000; Mannervik et al., 1999). The level of cellular
Oct-3/4 expressed in a tissue-specific manner in early
embryos (Scholer et al., 1989), including cardiac progen-
itors (Tam and Schoenwolf, 1999), may favor interac-
tions of lineage-specific transcription factors and bind-
ing of the latter to specific gene promoters.
Although further investigation is required to ensure
that these mechanisms can be applied to cultured ES
cells, our findings confer to Oct-3/4 an additive physio-
logical function as a key player in the process of meso-
dermal and cardiac commitments of the embryonic epi-
blast and ES cells. They further add to the emerging idea
that Oct-3/4 acts in a gene dosage-dependent manner
as a transcriptional organizer in a complex network of
tissue-specific transcription factors in early stages of
stem cell and blastocyst differentiation (Brehm et al.,
1997; Niwa et al., 2000; Shimozaki et al., 2003).
Experimental Procedures
ESCell Propagation, Differentiation, and Stimulationwith Nodal,
TGFb, and BMP2
CGR8 ES cells were propagated without any conditioned medium
or feeder cells (Meyer et al., 2000; see Supplemental ExperimentalProcedures) and were stimulated in serum-free medium for 24 hr
with TGFb (2.5 ng/ml), BMP2 (5 ng/ml), or nodal (10 ng/ml) in
Glasgow-BHK21 medium free of TGFb or BMP2 as measured by
ELISA (Kits R&D). Concentrations of added TGFb and BMP2 over
the 24 hr were further checked by ELISA every 8 hr.
Oct-3/4, Smad siRNAs, Oct-3/4 Antisense Oligonucleotides,
and Expression Vectors
The sequences and vectors are described in Supplemental Experi-
mental Procedures.
Injection and Culture of Mouse Blastocysts
Oct-3/4 siRNA was hybridized to the MPG2 gene delivery system
(2.5 mM MPG2 and 300 nM siRNA) as previously described (Simeoni
et al., 2003). In vitro analysis of blastocysts revealed that siRNA-
mediated knockout of Oct-4 lasts for at least 48 hr (n = 6). Blasto-
cysts were flushed out of the uterus of naturally mated pregnant
C57BL/6 mice (Charles River), cultured for a few hours in M2 me-
dium, and microinjected with the carrier MPG2 alone or bound to
a neutral siRNA (sense 50-AGGUCUGCAGACAGACCACdtdt-30 and
antisense 50-GUGGUCUGUCUGUCUGCAGACCUdtdt-30) or with
the Oct-3/4 siRNA bound to MPG2 using a Leica Microsystems
transgenic platform. Blastocysts were then cultured in M16 medium
supplemented with 2% fetal calf serum and 100 ng/ml stem cell fac-
tor (Mitsunari et al., 1999). After 5 days, the blastocysts were lysed
and RNA was extracted using a kit (Palm Laser) prior to real-time
PCR analysis. In some experiments, blastocysts were reimplanted
in pseudopregnant mice and embryos were collected at E9.5 and
E12.5.
Immunostaining and In Situ Hybridization in Embryos
Embryos were collected at E9.5 and E12.5, fixed in 4% paraformal-
dehyde, equilibrated in 30% sucrose, embedded in OCT, frozen, and
sectioned before in situ hybridization using the Nkx2.5 and a-actin
probes. To visualize the structure of the myocardium, they were
stained with the anti-b-MHC and -sarcomeric actinin antibody. A de-
tailed protocol is described in Supplemental Experimental Proce-
dures.
Antibodies, Western Blotting, and Immunocytochemistry
Antibodies used in this study are described in Supplemental Experi-
mental Procedures.
RNA Extraction, Reverse Transcription Reaction, and PCR
Total cellular RNA was isolated from ES cells or EBs using an RNA
extraction kit (Zymo Research). One microgram of RNA was reverse
transcribed using the Mu-MLV reverse transcriptase (Invitrogen).
PCR was performed as previously described (Meyer et al., 2000).
Primers sequences are given in Supplemental Experimental Proce-
dures.
Chromatin Immunoprecipitation Assay
ChIP was performed using a standard protocol (Wells and Farnham,
2002). Briefly, ES cell lysates were precleared with salmon sperm
DNA and protein A, and ChIP was performed with 5 mg anti-Smad4
antibody (Santa Cruz Biotechnology) or an irrelevant antibody.
DNA fragments were used in real-time PCR using the primers
50-CAGGGCATGGTGTAGGAGCAGA-30 and 50-AAGGAGACGGGAT
TAGGAGGAG-30 for the proximal enhancer and 50-CCAAAAG
AGAAATCACAATCCA-30 and 50-GGCTACAACCTCCCCACACC-30
for the distal enhancer. Real-time PCR was performed as described
above. Quantification of the amplicon was performed by calculating
the area under the melting curve. The amplicon was then run on a gel
and sequenced.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and five figures and are available at http://www.developmentalcell.
com/cgi/content/full/11/4/535/DC1/.
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